Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

• Published in: Cancer letters Vol. 343; no. 2; pp. 172 - 178
• Main Authors: Xu, Xiao-Jun, Tang, Yong-Min
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 28.02.2014; Elsevier Limited
• Subjects: Adverse event; Cancer; Cardiac arrhythmia; Chemokines; Chimeric antigen receptor; Clinical trials; Cytokine release syndrome; Cytokines; Cytokines - metabolism; Fever; Headaches; Hematology, Oncology and Palliative Medicine; Humans; Immune system; Immunotherapy; Liver; Lymphocytes; Nausea; Neoplasms - immunology; Neoplasms - therapy; Proteins; Receptors, Antigen, T-Cell - therapeutic use; Recombinant Fusion Proteins - therapeutic use; Respiratory distress syndrome; Safety; Syndrome; Adverse event; Cytokine release syndrome; Safety; Chimeric antigen receptor; Cancer

Highlights • Cytokine release syndrome (CRS) is a fatal complication in CAR-T cell therapy. • CRS correlates with CAR structures, underlying diseases and cytokine gene polymorphisms. • CRS may be reduced by dose-escalation scheme, designing safer CARs and short-lived CAR-T cell infusion. • CRS can b...